Berberine and Etoposide Exert Synergistic Anticancer Effects in A431 Epidermoid Carcinoma Cells
ACS Omega · 13.10.2026 · 11 (40) · 61344-61357
DOI: 10.1021/acsomega.6c06421 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Omega, online erschienen am 02.10.2026. Verfasst von Zeynep Özlem Cinar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biochemistry, Life Sciences Center, Vilnius University, LT-10257 Vilnius, Lithuania. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lietuvos Mokslo Taryba, Vilnius University.
Abstract (Originalsprache)
Berberine, a natural isoquinoline alkaloid derived fromCoptidis rhizoma has long been used in traditional medicine and has recently attracted attention for its potential role in cancer therapy. Emerging evidence suggests that berberine can inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9), a key regulator of lipid metabolism that has also been implicated in tumor biology. While the role of PCSK9 in cardiovascular diseases is well established, its contribution to cancer progression and therapeutic response remains incompletely understood. Here, we investigated whether berberine-mediated inhibition of PCSK9 could enhance the efficacy of chemotherapeutic agents. Berberine reduced PCSK9 expression at both mRNA and protein levels and increased LDLR abundance in A431 cells, which exhibit high basal PCSK9 expression. Functionally, berberine decreased cell viability in a dose-dependent manner and exhibited a strong synergistic interaction with etoposide, according to the HSA synergy score. Mechanistic analyses indicated that berberine enhances etoposide-induced cytotoxicity, at least in part by delaying the resolution of DNA-damage associated signals. Importantly, genetic silencing of PCSK9 recapitulated the sensitizing effect of berberine, while palmatine, a structurally related compound with lower efficacy in reducing PCSK9 levels, showed decreased synergy with etoposide, although evaluated under a different range of concentrations. Collectively, these findings support a role for PCSK9 in modulating cellular sensitivity to etoposide and suggest that berberine may act as a potential adjuvant in this context.
Autor:innen und Institutionen
- Institute of Biochemistry, Life Sciences Center, Vilnius University, LT-10257 Vilnius, Lithuania.
- Department of Biological Models, Institute of Biochemistry, Life Sciences Center, Vilnius University, LT-10257 Vilnius, Lithuania.
- Institute of Biosciences, Life Sciences Center, Vilnius University, LT-10257 Vilnius, Lithuania.
ORCID-Profile: Giulio Preta
Förderung
- Lietuvos Mokslo Taryba
- Vilnius University
Zitieren
APA
Cinar, Z. Ö., Šatrova, V., Vijaya, A. K., Babonaitė-Aleksieju̅nė, M., Glebavičiu̅tė, G., Burokas, A., & Preta, G. (2026). Berberine and Etoposide Exert Synergistic Anticancer Effects in A431 Epidermoid Carcinoma Cells. ACS Omega, 11(40), 61344-61357. https://doi.org/10.1021/acsomega.6c06421
Vancouver
Cinar ZÖ, Šatrova V, Vijaya AK, Babonaitė-Aleksieju̅nė M, Glebavičiu̅tė G, Burokas A, et al. Berberine and Etoposide Exert Synergistic Anticancer Effects in A431 Epidermoid Carcinoma Cells. ACS Omega. 2026;11(40):61344-61357. doi:10.1021/acsomega.6c06421
BibTeX
@article{Cinar2026,
author = {Cinar, Zeynep Özlem and Šatrova, Valerija and Vijaya, Akshay Kumar and Babonaitė-Aleksieju̅nė, Milda and Glebavičiu̅tė, Goda and Burokas, Aurelijus and Preta, Giulio},
title = {Berberine and Etoposide Exert Synergistic Anticancer Effects in A431 Epidermoid Carcinoma Cells},
journal = {ACS Omega},
year = {2026},
volume = {11},
number = {40},
pages = {61344--61357},
doi = {10.1021/acsomega.6c06421}
}
EUVIMED